The current socioeconomic context advises the creation of an adequate environment for the biosimilar drugs in terms of regulation and consumption, in order to encourage investment by biotechnology companies. But these products are here to stay because whatever the economic situation, they are a decisive tool in the sustainability and the universality of the health system.
Thus, the benefits of using biosimilars in the market are directly proportional to their growth and implementation, since the savings they represent and of which we have already spoken in this blog, translates into an improvement in the accessibility to treatments for citizens.
Therefore, since biosim We believe that a joint effort is necessary between the actors involved to create an adequate legislative framework that transfers confidence to health professionals in the use and consumption of biosimilar drugs.
For example, we defend the development of specific reimbursement rules that create the conditions for the development of the biosimilars market in Spain, a process linked, of course, to a constant supply of information to professionals in the sector and patients. Breaking down barriers, mainly cultural ones, is essential to achieve these objectives.
If they do not reach a minimum market volume, they will not be able to establish themselves as a sustainable alternative to the reference biological medicines.
